Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

JPMorgan reinstates coverage of Tritax Big Box at 'overweight'

(Sharecast News) - JPMorgan Cazenove reinstated coverage of Tritax Big Box on Wednesday following a period of restriction, with an 'overweight' rating and 180p price target, which implies 32% upside. "We update for newsflow and results while restricted, including guidance that the company sees earnings growth potential of 50% to FY2030," the bank said.

"This will come in the form of a hockey stick, with intense investment and disposals in the near term leading to strong EPS growth in the medium term."

JPM said that on its analysis, NAV growth could be stronger, with modest underlying capital growth boosted by development profit from datacentres.

"Taking a step back, listed UK property hasn't been able to catch a break over the last 12 months - down 17% with top-down drivers all going the 'wrong' way," it said.

"What would help the sector - and we got a taster of its potential last week - is rate cuts, as UK names rose as much as 5% (from the lows) catalysed by US non-farm payroll data."

JPM said it thinks the value in UK property is evident and it expects that over the coming 12-18 months the sector should re-rate higher on continued operational resilience and alleviating rate headwinds.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.